What's Happening?
Aspera Biomedicines Inc., a biotechnology company focused on developing therapies targeting cancer stem cells, has successfully launched its second ADAR1p150 protein crystallization experiment aboard the SpaceX CRS-34 mission to the International Space Station
(ISS). The experiment aims to advance the development of an oral formulation of Rebecsinib, a therapeutic designed to target cancer stem cells by inhibiting the ADAR1 protein. This mission, part of NASA's In Space Production Applications (InSPA) Phase 2 award, utilizes Redwire Corporation's Pharmaceutical In-space Laboratory (PIL-BOX) technology to crystallize proteins in microgravity, which allows for structural details that are difficult to achieve on Earth. The experiment is expected to provide insights into the drug-target interaction, potentially leading to improved formulations of Rebecsinib.
Why It's Important?
The successful launch and operation of this experiment in microgravity is significant for cancer research, particularly in understanding and targeting cancer stem cells, which are known to drive relapse in many cancers. By elucidating the mechanism of action of Rebecsinib, Aspera Biomedicines aims to develop an oral formulation that could prevent cancer stem cell regeneration and immune system evasion in over 20 types of cancer. This research could lead to more effective treatments for high-risk cancers such as acute myeloid leukemia and glioblastoma, potentially improving patient outcomes and expanding access to innovative cancer therapies.
What's Next?
Following the successful docking of the Dragon spacecraft with the ISS, the crystallization experiment is now underway. Aspera Biomedicines plans to use the structural insights gained from this mission to guide the development of next-generation ADAR1 inhibitors and oral formulations of Rebecsinib. The company has received FDA Investigational New Drug (IND) approval for Rebecsinib and is preparing to begin Phase 1 clinical trials in patients with high-risk myelofibrosis and secondary acute myeloid leukemia. These developments could pave the way for broader therapeutic applications and further clinical advancements in cancer treatment.
